Endometrial Cancer | Topics

Phase 2 ENPAC Trial Shows Feasibility of Enzalutamide Triplet in Endometrioid Endometrial Cancer
March 25, 2021

The androgen receptor inhibitor enzalutamide, an approved therapy for certain types of prostate cancer, has shown activity for the treatment of patients with recurrent or advanced endometrioid endometrial cancer.

Addition of Olaparib to Cediranib Does Not Induce Superior Efficacy in Advanced Endometrial Cancer
March 22, 2021

The combination of cediranib and olaparib demonstrated modest efficacy in patients with recurrent, metastatic, or persistent endometrial cancer; however, this was not significantly different compared to cediranib alone.

Pembrolizumab/Lenvatinib Combo Shows Survival Benefit in Advanced Endometrial Cancer
March 19, 2021

Following a prior announcement that the phase 3 KEYNOTE-775 trial met both primary end points of progression-free and overall survival benefit, data for the pembrolizumab/lenvatinib combination were presented at the Society of Gynecologic Oncology 2021 Annual Meeting on Women’s Cancer.